HRADECKÁ, Irena, Barbora ŘÍHOVÁ and Regina DEMLOVÁ. The Cost Study of Cetuximab and Panitumumab in The First-Line Treatment of Mcrc in The Czech Republic. 2017. ISSN 1098-3015.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The Cost Study of Cetuximab and Panitumumab in The First-Line Treatment of Mcrc in The Czech Republic
Authors HRADECKÁ, Irena (203 Czech Republic, belonging to the institution), Barbora ŘÍHOVÁ (203 Czech Republic, guarantor, belonging to the institution) and Regina DEMLOVÁ (203 Czech Republic).
Edition 2017.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 5.494
RIV identification code RIV/00216224:14110/17:00098995
Organization unit Faculty of Medicine
ISSN 1098-3015
UT WoS 000413599900143
Keywords in English Cetuximab; Panitumumab
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 16/3/2018 18:16.
Abstract
Meeting abstract The Cost Study of Cetuximab and Panitumumab in The First-Line Treatment of Mcrc in The Czech Republic.
PrintDisplayed: 22/7/2024 10:20